Optimizing pathological response assessment after neoadjuvant immunotherapy: linking clinical practice to drug development

Immune checkpoint blockade (ICB) has transformed our understanding of cancer therapy and rendered cures a regularly attainable goal. The basic concept of training the host’s immune system to reject cancer demonstrated its curative potential first in the advanced disease setting. However, the neoadjuvant setting offers a unique opportunity to harness the power of ICB while delivering the coup de grâce…